First Trust Advisors LP Buys 2,143,211 Shares of Sarepta Therapeutics, Inc. $SRPT

First Trust Advisors LP lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 107.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,135,788 shares of the biotechnology company’s stock after purchasing an additional 2,143,211 shares during the period. First Trust Advisors LP’s holdings in Sarepta Therapeutics were worth $89,995,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Kestra Advisory Services LLC bought a new position in Sarepta Therapeutics in the fourth quarter worth about $25,000. iSAM Funds UK Ltd bought a new stake in Sarepta Therapeutics during the 3rd quarter valued at approximately $25,000. Ancora Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the period. Allworth Financial LP grew its holdings in shares of Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the period. Finally, Larson Financial Group LLC raised its position in shares of Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 851 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $15.68 on Friday. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56. The business’s 50 day moving average price is $17.14 and its 200-day moving average price is $18.95. Sarepta Therapeutics, Inc. has a 52 week low of $11.12 and a 52 week high of $25.32. The stock has a market cap of $1.66 billion, a P/E ratio of -16.33, a P/E/G ratio of 0.17 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. The company had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.15 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the company earned ($3.42) EPS. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on SRPT shares. Piper Sandler lowered their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research note on Thursday, July 9th. Zacks Research downgraded Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Royal Bank Of Canada raised their price objective on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research report on Tuesday, April 7th. Weiss Ratings upgraded shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Nine analysts have rated the stock with a Buy rating, nine have given a Hold rating and seven have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $23.90.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.